Rutger H.T. Koornstra
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, CAR-T cell therapy research, Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways
Most-Cited Works
- → Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma(2018)1,816 cited
- → Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo(2020)425 cited
- → Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial(2021)373 cited
- → Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial(2020)271 cited
- → The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer(2010)268 cited
- → Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells(2015)232 cited
- → Lactate dehydrogenase: a marker of diminished antitumor immunity(2020)201 cited
- → Management of fatigue in patients with cancer – A practical overview(2014)120 cited
- → Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands(2016)104 cited
- → Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma(2019)84 cited